BofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $12 from $14 and keeps a Neutral rating on the shares after the company issued guidance for 2025 and reiterated corporate priorities, including the establishment of Danyelza and radiopharmaceutical business units. The firm sees the realignment as a plus given the focus on Danyelza may help a waning launch, though it also notes guidance for this year “implies another year of rebuilding to growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
- Y-mAbs Therapeutics price target lowered to $7 from $11 at Morgan Stanley
- Y-mAbs Therapeutics price target lowered to $21 from $23 at Oppenheimer
- Positive Growth Prospects and Strategic Developments Drive Buy Rating for Y-Mabs Therapeutics
- Y-mAbs Therapeutics Reports 2024 Financial Results